MedTrace Logo

Efficacy and Safety of Cipros 20 Association on Dyslipidemia Treatment

NCT03540355 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 406

Last updated 2026-01-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of Cipros 20 association in the treatment of dyslipidemia treatment.

Conditions

  • Dyslipidemias

Interventions

DRUG

Cipros 20 association

oral, once a day

DRUG

Crestor 20 mg

Oral, once a day

Sponsors & Collaborators

  • EMS

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-02
Primary Completion
2025-01-23
Completion
2025-01-23

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03540355 on ClinicalTrials.gov